4/8
08:15 am
verv
Verve Therapeutics, Inc. (NASDAQ: VERV) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $15.00 price target on the stock.
Low
Report
Verve Therapeutics, Inc. (NASDAQ: VERV) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $15.00 price target on the stock.
4/8
06:23 am
verv
Verve Therapeutics initiated with bullish view at H.C. Wainwright
Medium
Report
Verve Therapeutics initiated with bullish view at H.C. Wainwright
4/8
06:23 am
verv
Verve Therapeutics initiated with bullish view at H.C. Wainwright
Medium
Report
Verve Therapeutics initiated with bullish view at H.C. Wainwright
4/3
08:45 am
verv
Rating for VERV
Medium
Report
Rating for VERV
2/28
10:57 am
verv
Verve Therapeutics, Inc. (NASDAQ: VERV) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
Low
Report
Verve Therapeutics, Inc. (NASDAQ: VERV) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
2/28
10:57 am
verv
Verve Therapeutics, Inc. (NASDAQ: VERV) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
Low
Report
Verve Therapeutics, Inc. (NASDAQ: VERV) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
2/28
10:46 am
verv
Rating for VERV
Low
Report
Rating for VERV
2/28
10:46 am
verv
Rating for VERV
Low
Report
Rating for VERV